Michael Diem Joins Medgenics
The genomic medicine company, Medgenics Inc., has appointed Michael Diem, former head of corporate strategy and corporate development at AstraZeneca PLC, senior vice president of business and corporate development.
You may also be interested in...
Big pharma has been big news recently, with politicians and the general public wading into industry debates on drug pricing, profit-making and trial transparency under the gleeful eye of the international press. Unsurprisingly, pharma has come out on the losing side of these debates, its scientific accomplishments forced into the shadows by the actions of executives such as Martin Shkreli, who have ensured that the spotlight is firmly on the people behind the businesses rather than the products they manufacture.
GarmaMabs Pharma has appointed Martine J. George an independent board member.
Mylan has appointed Kenneth Parks chief financial officer (CFO).